A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

Pfizer

Status: Completed

Conditions: Thromboembolism

Study type: Observational

Funder types: Industry

Identifiers

NCT05643885

B0661183

NCT05643885 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.

Enrollment: 7,304 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
• Evidence of active cancer
• At least 1 claim for apixaban or low molecular weight heparin (LMWH)
• Age 18 years or older

Exclusion criteria

• diagnosis of atrial fibrillation/flutter
• procedure for mechanical heart valve or inferior vena cava filter
• VTE diagnosis in the baseline period
• anticoagulant therapy in the baseline period
• pregnancy

Trial design

7,304 participants in 2 patient groups

apixaban

Description:

patients treated with apixaban

Low molecular weight heparin (LMWH)

Description:

patients treated with low molecular weight heparin